Fig. 2.

Dose-dependent effect of several inhibitory compounds on chondrosarcoma cell lines. (a–f) Cell viability (WST-1 assays) measured after the treatment of wild-type and mutant IDH chondrosarcoma cell lines with increasing concentrations of enasidenib (a), ivosidenib (c), vorasidenib (d), CB-839 (e) and metformin (f) for 72 h. IDH mutation status of chondrosarcoma cell lines and IC5₅₀ values for enasidenib treatments are shown (b). Error bars represent the standard deviation of three independent biological replicates.